A randomized, double-blind, placebo-controlled, crossover trial of D-cycloserine in schizophrenic patients with the conventional antipsychotic medicatio

Not Applicable

• Conditions: Schizophrenia

• Registration Number: JPRN-UMIN000000468
• Lead Sponsor: Tokyo Medical and Dental University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-08-18
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who meet the following criteria should be excluded: 1) under being treated with the structured psychotherapies or cognitive-behavioral therapies within 12 weeks before the beginning of this study; 2) DSM-IV diagnosis of substance-related disorders within 24 weeks before the beginning of this study; 3) under being treated with the electroconvulsive therapy within 12 weeks before the beginning of this study; 4) during pregnancy and lactation or the possible pregnancy within 30 days after the end of this study; 5) suicide attempt within 24 weeks before the beginning of this study; 6) history or complication of convulsive disorders; 7) history of hypersensitivity to D-cycloserine or lactose; 8) complication of serious organic brain diseases; 9) complication of serious somatic disorders including hepatopathy, nephropathy, cardiopathy, etc.; 10) implantation of metal materials in the body; 11) insertion of a cardiac pacemaker; 12) under being treated with D-cycloserine; 13) other conditions that are considered to be inappropriate to the present trial by its investigators.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) PANSS (Scores of positive, negative, and total symptoms) 2) SANS (Scores of negative symptoms)

Secondary Outcome Measures

Name	Time	Method
1) PANSS (Scores of the individual subgroups of positive symptoms) 2) PANSS (Scores of the individual subgroups of negative symptoms) 3) SANS (Scores of the individual subgroups of negative symptoms) 4) GAS (Scores of the Global Assessment Scale) 5) HAM-D (Scores of the Hamilton Rating Scale for Depression) 6) DIEPSS (Scores of the Drug-Induced Extra-Pyramidal Symptoms Scale) 7) AIMS (Scores of the Abnormal Involuntary Movement Scale) 8) EQS (Scores of the Emotional Intelligence Scale) 9) The serum levels of D-cycloserine 10) The serum levels of D-serine 11) Brain MRI